Endoscopic Endonasal Approach for Resection of Clival Chordomas: A Systematic Review and Meta-Analysis.

Authors

Rudolfh Batista Arend, Natan Lucca Lima, Pedro Henrique Ieggli, Bruno Zilli Peroni, Daniel Marchi Kieling, Gabriel Lima Vieira Barbosa, Lucas Teles da Silva, Ana Clara Uliana Rezende, Amanda Delai Lobo, Marcos Henrique da Silva Mezzari, Amanda Karla Rodrigues Oliveira Eulálio, Matheus Bassan Chenta, Thayne Alexsandra Carneiro da Costa Sousa, Beatriz Gonçalves da Silva Miroski Gerente, Ananda Reis do Patrocínio Rodrigues, Wagner Rios-Garcia, Pierre-Olivier Champagne, Alex Roman, Cleiton Formentin, Martin Batista Coutinho da Silva, Guilherme Gago

Published in

Operative neurosurgery (Hagerstown, Md.). Jul 30, 2026. Epub Jul 30, 2026.

Abstract

Clival chordoma is a rare, locally invasive tumor originating from notochord remnants. The endoscopic endonasal approach (EEA) offers direct midline access, but the ideal balance between radicality and safety remains debated because of perioperative complications and mortality. The aim of this study was to synthesize oncologic and safety outcomes of EEA for clival chordomas, focusing on extent of resection, recurrence, and complications.
PubMed, Embase, Scopus, and Web of Science were searched through September 2025. We included observational studies of clival chordoma treated through EEA reporting extent of resection and outcomes. Exclusion criteria included alternative approaches, nonchordoma histologies, non-English/Spanish/Portuguese reports, series with <5 patients, and secondary evidence. Single-group random-effects meta-analyses of proportions were performed; heterogeneity was summarized with I2.
We included 18 observational studies comprising 1197 patients. The mean follow-up was 55.1 months. Pooled gross total resection was 48.3% (95% CI: 39.6-57.6; I2 = 94%). Near-total, subtotal, and partial resection rates were 29.2%, 27.2%, and 9%, respectively. Mortality during follow-up was 10.8% (95% CI: 5.7-19.4; I2 = 83%). Pooled cerebrospinal fluid leak rate was 12.4% (95% CI: 6.8%-16.6%; I2 = 64%). Complications included cranial nerve palsy 7.5% (95% CI: 4.4%-12.4%; I2 = 68%), paresis 4.1% (95% CI: 2.3%-7.1%; I2 = 40%), diplopia 3.7% (95% CI: 0.0%-13.4%; I2 = 51%), brain infarction 1.2% (95% CI: 0.02.8%; I2 = 14%), major hemorrhage 0.3% (95% CI: 0.0%-1.3%; I2 = 6%), and hematoma 0.2% (95% CI: 0.0%-1.2%; I2 = 0%).
In contemporary EEA for clival chordomas, about half of the patients achieve gross total resection. Recurrence approaches ∼32% at reported follow-up. Morbidity is driven chiefly by cranial nerve deficits (∼8%), whereas major vascular and bleeding events are uncommon.
CRD420251155783.

PMID:
42525859
Bibliographic data and abstract were imported from PubMed on 30 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.